AmeriCann Records Historic Quarterly Net Income and Revenue

Company achieved impressive quarterly growth for both net income and EBITDA

BOSTON, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- AmeriCann Inc. (ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, announces the release of financial and operational results for its fiscal quarter ending June 30, 2022.

Financial Overview

The Company achieved a significant increase in year-over-year quarterly net income and revenue, with both being records for the Company for the quarter ending June 2022. Revenue increased over 36% for the quarter ended June 2022 relative to the quarter ended June 2021, an increase of $213,188. Quarterly gross margins were 98.5%.

AmeriCann also announced that revenue for July 2022 set an all-time monthly record for the Company.

The increase in financial performance is attributable to greater revenue received from products produced and manufactured at Building 1, the Company's initial building at its Massachusetts Cannabis Center development in Freetown, Massachusetts.

Building 1 is a 30,000-square-foot cultivation greenhouse and processing facility that utilizes AmeriCann’s proprietary “Cannopy” cultivation system. Building 1 is fully occupied by Bask Inc., an existing Massachusetts licensed vertically integrated cannabis operator.

AmeriCann receives base rent and a Revenue Participation Fee of 15% of all gross monthly sales of cannabis, cannabis-infused products and non-cannabis products produced at the Massachusetts Cannabis Center. As operations commenced and accelerated at Building 1, AmeriCann established many milestones for its financial performance.

A summary of operational highlights included the following:

  • AmeriCann’s Operating Revenue from Building 1 increased over 36% from the quarter ended June 30, 2021, to the quarter ending June 30, 2022. Net Income increased by $261,689 to $162,734.

  • The Company achieved positive Adjusted EBITDA for the quarter of $438,890, an increase of 84% over the quarter ending June 2021. Adjusted Operating EBITDA margins for the quarter were 55.0%.

  • The manufacturing of cannabis-infused products, including the 1906 branded “Drops,” Howl’s Tincture, and Harpoon Extracts, has increased dramatically at the Massachusetts Cannabis Center. Sales of manufactured infused products are expected to be even stronger as continual increases in production and sales for 1906 “Drops” are realized.

  • The 1906 branded “Drops” has been the top-selling edible product in the Massachusetts market. Howl’s Tincture was the top-selling brand in the tincture category.

  • For the first five months of 2022, the total cannabis sales revenue for the Massachusetts market was $708 million, which was 16% greater than the first five months of 2021. The annualized revenue estimate based on the first five months of 2022 is approximately $1.7 billion. Experts believe the market will exceed $1.8 billion annually.

  • The total Massachusetts market has sold $3.2 billion since the inception of the Commonwealth’s regulated cannabis program.

See definitions of non-GAAP measures later in this release.

Management Commentary

“The June 2022 financial results highlight the strength of our operations,” said AmeriCann CEO and President Tim Keogh. “Record revenue, combined with our high gross margins and low operating costs, resulted in all-time profits and cash flow for the company. Additionally, July 2022 revenue, which was not included in the most recent quarterly financials, set a monthly record.”

AmeriCann is in the final design phase of the expansion of its MCC development in Freetown, Massachusetts. AmeriCann has secured cultivation and manufacturing licenses for Building 2 – the next phase of the Massachusetts Cannabis Center. Building 2 calls for approximately 400,000 additional square feet of cannabis cultivation, manufacturing and distribution infrastructure.

About AmeriCann

AmeriCann (OTCQB:ACAN) develops and leases cannabis cultivation, processing and product manufacturing facilities.

AmeriCann uses greenhouse technology which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25% fewer lights, and utility bills are up to 75% less than in typical warehouse cultivation facilities. As such, AmeriCann's Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs.

AmeriCann is also designing GMP-Certified cannabis extraction and product manufacturing infrastructure. AmeriCann has secured licenses to produce cannabis-infused products including beverages, edibles, topicals and concentrates. AmeriCann plans to operate a Marijuana Product Manufacturing business at the Massachusetts Cannabis Center.

To learn more about the Massachusetts Cannabis Center click HERE to watch a short video.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise.

About Non-GAAP Financial Measures

The Company uses "adjusted EBITDA," as a non-GAAP financial measure to evaluate financial performance such as period-to-period comparisons. This non-GAAP measure is not defined under U.S. GAAP and should be considered in addition to, not as a substitute for, indicators of financial performance reported in accordance with U.S. GAAP. The Company may use non-GAAP measures that are not comparable to measures with similar titles reported by other companies. Also, in the future, the Company may disclose different non-GAAP financial measures in order to help investors more meaningfully evaluate and compare the Company's future results of operations to its previously reported results. The Company encourages investors to review its financial statements and publicly filed reports in their entirety and not rely on any single financial measure. The section titled "Reconciliation of Non-GAAP Financial Measures" includes a detailed description of this measure as well as a reconciliation to its most similar U.S. GAAP measure.

Reconciliation of Non-GAAP Financial Measures

The Company defines adjusted EBITDA as net income adjusted to exclude the impact of interest expense, interest income, income taxes, depreciation, depletion and amortization, stock-based compensation, impairment, and the plus or minus change in fair value of derivative assets or liabilities. The Company believes adjusted EBITDA is relevant because it is a measure of cash flow available to fund capital expenditures and service debt and is a metric used by some industry analysts to provide a comparison of its results with its peers. The following table presents a reconciliation of the Company's non-GAAP financial measures to the nearest GAAP measure.

Quarter Ending June 30, 2022 Highlights
June 2022 Q vs. June 2021 Q        
  Quarters ended    
  June 30, 2022
  June 30, 2021
  $ Change % Change
Rental income - related party $797,734  $584,546  $213,188  36%
Net income (loss) $162,734  $(98,955) $261,689  264%
Interest income  (1,822)  (4,392)  2,570  59%
Interest expense  152,445   215,667   (63,222) -29
Interest expense - related party  13,052   13,051   1  0%
Depreciation and amortization  112,481   112,711   (230) -0
EBITDA $438,890  $238,082  $200,808  84%
EBITDA $438,890  $238,082  $200,808  84.3%
EBITDA Margin  55.0%  40.7%  94.2%  
Gross Margin  98.5%  98.7%  -0.2%  
June 2022 Q vs. March 2022 Q        
  Quarters ended    
  June 30, 2022 March 31, 2022 $ Change % Change
Rental income - related party $797,734  $667,366  $130,368  20%
Net (loss) income $162,734  $24,240  $138,494  571%
Interest income  (1,822)  (3,119)  1,297  42%
Interest expense  152,445   151,089   1,356  1%
Interest expense - related party  13,052   12,907   145  1%
Depreciation and amortization  112,481   112,480   1  0%
EBITDA $438,890  $297,597  $141,293  47%
EBITDA $438,890  $297,597  $141,293  47.5%
EBITDA Margin  55.0%  44.6%  108.4%  
Gross Margin  98.5%  98.4%  0.1%  


Contact Information:
@ACANinfo on Twitter
@AmeriCann on Facebook
@AmeriCannInc on Instagram
AmeriCann, Inc on LinkedIn

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
310.299.1717 Office

A photo accompanying this announcement is available at

AmeriCann, Inc. Massachusetts Cannabis Center